Director/PDMR Shareholding

RNS Number : 1294K

Circassia Pharmaceuticals Plc

23 August 2019

 

Grant of options

Oxford, UK - 23 August 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has granted options ("Options") today over 1,884,602 new ordinary shares of 0.08 pence each in the Company ("Ordinary Shares") (representing 0.50% per cent. of the Company's issued share capital) to certain directors of the Company under the 2019 Performance Share Plan.

The Options have been granted at a price of 0.08 pence per Ordinary Share, will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to share price and sales performance conditions.

Name	Position	Options Issued	Awards and Options Held Post Issue
Steven Harris	Chief Executive Officer	803,200	1,961,771
Julien Cotta	Chief Financial Officer	518,728	1,329,194
Rod Hafner	Senior Vice President of R&D	562,674	1,250,681

Contacts

Circassia Steve Harris, Chief Executive Officer Julien Cotta, Chief Financial Officer Rob Budge, Corporate Communications	Tel: [phone]
Peel Hunt (Nominated Adviser and Joint Broker) James Steel / Dr Christopher Golden	Tel: [phone]
Numis Securities (Joint Broker) James Black / Freddie Barnfield	Tel: [phone]
FTI Consulting Simon Conway / Ciara Martin	Tel: [phone]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1.    Steven Harris 2.    Julien Cotta 3.    Rod Hafner
2.	Reason for the notification
a.	Position/status	1.    Chief Executive Officer 2.    Chief Financial Officer 3.    Senior Vice President of R&D
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Circassia Pharmaceuticals plc
b.	LEI	2138006YAT138TOGA556
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over Ordinary shares of 0.08p each. GB00B1VKB244
b.	Nature of the transaction	Award of share options granted under the 2019 Performance Share Plan over Ordinary Shares in Circassia
c.	Price(s) and volume(s)	Numbers 1 to 3 in the left hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above. Price(s) Volume(s) 1.    £0.0008 803,200 2.    £0.0008 518,728 3.    £0.0008 562,674
d.	Aggregated information ·     Aggregated volume ·     Price	n/a
e.	Date of the transaction	2019-08-23
f.	Place of the transaction	Outside a trading venue

 

END

 

 

DSHBLGDIGDDBGCX